Deep Learning-Derived Pathomic Features Predict NCIT Efficacy in Resectable Locally Advanced ESCC: Clinical Utility and Mechanistic Insights
Current Oncology · 2026
DOI: 10.3390/curroncol33030136 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Oncology, 2026. Verfasst von Kunrui Zhu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China. Hauptthemen laut MEDLINE: Esophageal Squamous Cell Carcinoma, Deep Learning, Neoadjuvant Therapy, Esophageal Neoplasms. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Chinese Society of Clinical Oncology, Beijing Xisike Clinical Oncology Research Foundation.
Abstract (Originalsprache)
Background
Esophageal squamous cell carcinoma (ESCC) is the predominant subtype of esophageal cancer, with poor outcomes following neoadjuvant chemoradiotherapy (NCRT). Neoadjuvant chemoimmunotherapy (NCIT) has emerged as a promising strategy, but reliable predictive biomarkers remain lacking. This study aimed to develop an AI-driven pathomic model for NCIT response prediction and explore its biological mechanisms.
Methods
We analyzed 269 H&E-stained whole-slide images (WSIs) from 198 ESCC patients (104 from Tongji Hospital, 94 from TCGA). Using ResNet152, we segmented WSIs into four tissue categories (tumor cells, stroma, lymphocytes, and necrosis), extracted spatially weighted pathomic features, and constructed the ECiT score via logistic regression. An integrated model combining the ECiT score with clinical variables (T stage, P53 status) was developed. Mechanistic analyses were performed using TCGA-ESCA and GSE160269 datasets.
Results
The integrated model achieved AUCs of 0.897 (training) and 0.809 (temporal validation), outperforming clinical (AUC = 0.624) and pathomic-only (AUC = 0.751) models. Mechanistically, a high ECiT score correlated with enhanced immune activation (elevated CD4+ memory T cell infiltration), while low scores were linked to endoplasmic reticulum (ER) stress-unfolded protein response (UPR) activation. EIF2S3 was identified as a key molecular mediator, correlating with three pathomic features, UPR activation, and poor prognosis.
Conclusions
This study may offer a preliminary indicator that could assist in personalized clinical decision-making. Correlative evidence suggests that the EIF2S3-mediated ER stress–UPR axis represents a potential candidate therapeutic target to overcome NCIT resistance, generating testable hypotheses to advance precision oncology for resectable locally advanced ESCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
- Institute of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
ORCID-Profile: Kunrui Zhu, Yiming Li, Shu Xia
Förderung
- National Natural Science Foundation of China
- Chinese Society of Clinical Oncology
- Beijing Xisike Clinical Oncology Research Foundation
Zitieren
APA
Zhu, K., Tong, J., Duan, Y., Li, Y., Feng, Y., Han, Y., Xiao, X., Han, Z., & Xia, S. (2026). Deep Learning-Derived Pathomic Features Predict NCIT Efficacy in Resectable Locally Advanced ESCC: Clinical Utility and Mechanistic Insights. Current Oncology. https://doi.org/10.3390/curroncol33030136
Vancouver
Zhu K, Tong J, Duan Y, Li Y, Feng Y, Han Y, et al. Deep Learning-Derived Pathomic Features Predict NCIT Efficacy in Resectable Locally Advanced ESCC: Clinical Utility and Mechanistic Insights. Current Oncology. 2026. doi:10.3390/curroncol33030136
BibTeX
@article{Zhu2026,
author = {Zhu, Kunrui and Tong, Jie and Duan, Yaqi and Li, Yiming and Feng, Yanqi and Han, Yuelin and Xiao, Xiangtian and Han, Zhuoyan and Xia, Shu},
title = {Deep Learning-Derived Pathomic Features Predict NCIT Efficacy in Resectable Locally Advanced ESCC: Clinical Utility and Mechanistic Insights},
journal = {Current Oncology},
year = {2026},
doi = {10.3390/curroncol33030136}
}
EUVIMED